Topical cyclosporine prevents vernal keratoconjunctivitis’ flare-ups
Published Online: August 26, 2011
Vernal keratoconjunctivitis (VKC) is a severe inflammatory disease that primarily affects children and is characterized by acute flare-ups that can permanently compromise vision. The physician’s primary objective is to prevent these acute flare-ups, as well as treat them when they do occur with the safest therapy available. The often remarkable recovery with steroids tempts the caretaker to overuse, and the chronic nature of this disease demands strict surveillance against steroid abuse, which inevitably leads to potential side effects such as cataract and glaucoma.
In a two-year study, published recently in The Journal of Allergy and Clinical Immunology (JACI), Lambiase et al. treated 31 patients with a long term, daily preventative treatment of a low concentration of cyclosporine (0.05%). They found that less than half of the patients had recurrences and remained recurrence-free for a significantly long period of time. These findings that cyclosporine significantly affected the course of VKC, demonstrates that it is a valid steroid-sparing therapy.
The Journal of Allergy and Clinical Immunology (JACI) is the official scientific journal of the AAAAI, and is the most-cited journal in the field of allergy and clinical immunology.